Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director | June 03, 2026 | June 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date June 03, 2026 · Filed June 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.46 · Expires 2036-06-02 | Direct | 17,786 |
Reported balance
After 2026-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-03 · Grant · Acquired 17,786 · Balance 17,786 F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option shall vest in full on the earlier of: (i) June 3, 2027 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Avidity Biosciences, Inc.
Report date February 27, 2026 · Filed February 27, 2026
Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 1
1 source rowRow 1 · 2026-02-27 · Disposition to issuer · Disposed 16,562 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Common StockSEC Table I · non-derivative | IndirectBy family trust | 0 |
Reported balance
After 2026-02-27 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-02-27 · Disposition to issuer · Disposed 131,372 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $33.62 · Expires 2035-06-09 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-27 · Disposition to issuer · Disposed 10,034 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.96 · Expires 2034-06-12 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-02-27 · Disposition to issuer · Disposed 13,489 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.47 · Expires 2033-01-19 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-27 · Disposition to issuer · Disposed 144,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.22 · Expires 2032-01-20 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-27 · Disposition to issuer · Disposed 115,500 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.34 · Expires 2031-02-01 | Direct | 0 |
Reported balance
After 2026-02-27 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-02-27 · Disposition to issuer · Disposed 12,500 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2024 Filed Jun 7, 2024 20:18 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,639 | $0.00 Strike: $16.41 | $0.00 |
DisclosureSEC source: 0001415889-24-015964 · form4-06072024_080608.xml · derivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,639 Underlying: Common Stock · 7,639 shares Expires 2034-06-04 F1 · derivative.exercise_date: The option shall vest in full on the earlier of: (i) June 5, 2025 or (ii) the date of the issuer's next annual meeting of its stockholders, subject to the reporting person's continued service to the issuer on the vesting date. Read SEC document |
| May 20, 2024 Filed May 21, 2024 21:05 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000075 · wk-form4_1716325502.xml · derivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 28,323 Underlying: Common Stock · 5,000 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. F3 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| May 20, 2024 Filed May 21, 2024 21:05 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,000 | $29.90 | $149,481.00 |
DisclosureSEC source: 0001599901-24-000075 · wk-form4_1716325502.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,830 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $29.23 to $30.36. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 20, 2024 Filed May 21, 2024 21:05 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 5,000 | $1.24 | $6,200.00 |
DisclosureSEC source: 0001599901-24-000075 · wk-form4_1716325502.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person on May 26, 2023. Read SEC document |
| April 19, 2024 Filed Apr 22, 2024 21:28 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000053 · wk-form4_1713821325.xml · derivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,323 Underlying: Common Stock · 5,000 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F4 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| April 19, 2024 Filed Apr 22, 2024 21:28 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,000 | $22.82 | $114,123.00 |
DisclosureSEC source: 0001599901-24-000053 · wk-form4_1713821325.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,830 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F3 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.25 to $23.56. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F2 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 13,500 RSUs under the Issuer's 2020 Incentive Award Plan and (ii) 1,330 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| April 19, 2024 Filed Apr 22, 2024 21:28 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 5,000 | $1.24 | $6,200.00 |
DisclosureSEC source: 0001599901-24-000053 · wk-form4_1713821325.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person. F2 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 13,500 RSUs under the Issuer's 2020 Incentive Award Plan and (ii) 1,330 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| April 03, 2024 Filed Apr 4, 2024 00:26 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 20,000 | $27.11 | $542,214.00 |
DisclosureSEC source: 0001599901-24-000051 · wk-form4_1712190395.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Indirect · By family trust Disclosed balance after: 253,872 F1 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.28. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 20:10 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000047 · wk-form4_1711051821.xml · derivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 38,323 Underlying: Common Stock · 5,000 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 20:10 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 5,000 | $23.97 | $119,847.50 |
DisclosureSEC source: 0001599901-24-000047 · wk-form4_1711051821.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,830 F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.69 to $24.56. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 13,500 RSUs under the Issuer's 2020 Incentive Award Plan and (ii) 1,330 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| March 19, 2024 Filed Mar 21, 2024 20:10 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 5,000 | $1.24 | $6,200.00 |
DisclosureSEC source: 0001599901-24-000047 · wk-form4_1711051821.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,830 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 13,500 RSUs under the Issuer's 2020 Incentive Award Plan and (ii) 1,330 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 00:41 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001599901-24-000042 · wk-form4_1710290471.xml · derivative · entry 5 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,323 Underlying: Common Stock · 25,000 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: All unexercised shares subject to the option are fully vested and exercisable as of the date hereof. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 00:41 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 2,641 | $22.00 | $58,102.00 |
DisclosureSEC source: 0001599901-24-000042 · wk-form4_1710290471.xml · nonDerivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,830 F3 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 13,500 RSUs under the Issuer's 2020 Incentive Award Plan and (ii) 1,330 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 00:41 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 25,000 | $22.04 | $550,915.00 |
DisclosureSEC source: 0001599901-24-000042 · wk-form4_1710290471.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,471 F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.23. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F1 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 16,141 restricted stock units (RSUs) under the Issuer's 2020 Incentive Award Plan and (ii) 1,330 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 00:41 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 25,000 | $1.24 | $31,000.00 |
DisclosureSEC source: 0001599901-24-000042 · wk-form4_1710290471.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,471 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes the following securities previously acquired by the Reporting Person: (i) 16,141 restricted stock units (RSUs) under the Issuer's 2020 Incentive Award Plan and (ii) 1,330 shares of common stock under the Issuer's 2020 Employee Stock Purchase Plan. Read SEC document |
| January 22, 2024 Filed Jan 23, 2024 20:14 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 1,859 | $10.13 | $18,831.67 |
DisclosureSEC source: 0001599901-24-000012 · wk-form4_1706040865.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,471 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs on January 20, 2024. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 22:24 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 19,441 | $0.00 Strike: $12.46 | $0.00 |
DisclosureSEC source: 0001209191-23-037533 · doc4.xml · derivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,441 Underlying: Common Stock · 19,441 shares Expires 2033-06-12 F1 · derivative.exercise_date: The option shall fully vest on June 13, 2024 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:36 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001209191-23-019672 · doc4.xml · derivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,323 Underlying: Common Stock · 100 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · derivative.exercise_date: 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:36 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 100 | $22.01 | $2,201.00 |
DisclosureSEC source: 0001209191-23-019672 · doc4.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,330 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| March 15, 2023 Filed Mar 17, 2023 20:36 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 100 | $1.24 | $124.00 |
DisclosureSEC source: 0001209191-23-019672 · doc4.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 01:30 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001209191-23-009938 · doc4.xml · derivative · entry 5 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,423 Underlying: Common Stock · 10,000 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 01:30 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 523 | $24.24 | $12,676.53 |
DisclosureSEC source: 0001209191-23-009938 · doc4.xml · nonDerivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,330 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.16 to $24.30 per share. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 01:30 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 9,477 | $23.62 | $223,890.33 |
DisclosureSEC source: 0001209191-23-009938 · doc4.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,853 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $23.16 to $24.08 per share. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 14, 2023 Filed Feb 16, 2023 01:30 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 10,000 | $1.24 | $12,400.00 |
DisclosureSEC source: 0001209191-23-009938 · doc4.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| January 20, 2023 Filed Jan 25, 2023 02:07 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 144,000 | $0.00 Strike: $22.47 | $0.00 |
DisclosureSEC source: 0001209191-23-004758 · doc4.xml · derivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,000 Underlying: Common Stock · 144,000 shares Expires 2033-01-19 F2 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 20, 2023 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| January 20, 2023 Filed Jan 25, 2023 02:07 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantCommon Stock | 18,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-004758 · doc4.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,330 F1 · shares: Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 20, 2023, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document |
| January 12, 2023 Filed Jan 18, 2023 01:50 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001209191-23-003625 · doc4.xml · derivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,423 Underlying: Common Stock · 10,000 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter. Read SEC document |
| January 12, 2023 Filed Jan 18, 2023 01:50 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 10,000 | $22.00 | $220,028.00 |
DisclosureSEC source: 0001209191-23-003625 · doc4.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,330 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.04. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 12, 2023 Filed Jan 18, 2023 01:50 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 10,000 | $1.24 | $12,400.00 |
DisclosureSEC source: 0001209191-23-003625 · doc4.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 22:40 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001209191-23-000358 · doc4.xml · derivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,423 Underlying: Common Stock · 40,000 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 22:40 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 40,000 | $22.01 | $880,568.00 |
DisclosureSEC source: 0001209191-23-000358 · doc4.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,330 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.16. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 29, 2022 Filed Jan 3, 2023 22:40 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 40,000 | $1.24 | $49,600.00 |
DisclosureSEC source: 0001209191-23-000358 · doc4.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 16, 2022 Filed Sep 1, 2022 00:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,499 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001209191-22-048195 · doc4.xml · derivative · entry 12 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,423 Underlying: Common Stock · 3,499 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter. F7 · balance_after: On June 11 2020, the Reporting Person filed a Form 3 which inadvertently overreported the number of options under this option grant due to a typographical error. The aggregate number of options beneficially owned has been updated in this Form 4 to reflect the total number of options held by the Reporting Person following the transactions reported on this Form 4 and the Reporting Person's previously filed reports. Read SEC document |
| August 16, 2022 Filed Sep 1, 2022 00:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 3,499 | $22.08 | $77,257.22 |
DisclosureSEC source: 0001209191-22-048195 · doc4.xml · nonDerivative · entry 7 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,330 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.30.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2022 Filed Sep 1, 2022 00:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 3,499 | $1.24 | $4,338.76 |
DisclosureSEC source: 0001209191-22-048195 · doc4.xml · nonDerivative · entry 6 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,829 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 15, 2022 Filed Sep 1, 2022 00:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 34,758 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001209191-22-048195 · doc4.xml · derivative · entry 11 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,922 Underlying: Common Stock · 34,758 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F6 · derivative.exercise_date: 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter. F7 · balance_after: On June 11 2020, the Reporting Person filed a Form 3 which inadvertently overreported the number of options under this option grant due to a typographical error. The aggregate number of options beneficially owned has been updated in this Form 4 to reflect the total number of options held by the Reporting Person following the transactions reported on this Form 4 and the Reporting Person's previously filed reports. Read SEC document |
| August 15, 2022 Filed Sep 1, 2022 00:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 27,740 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-22-048195 · doc4.xml · derivative · entry 10 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,740 shares Expires 2027-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: This option is exercisable as to vested and unvested shares. The option was granted on August 29, 2017 and 1/48th of the shares subject to the option vest monthly. Read SEC document |
| August 15, 2022 Filed Sep 1, 2022 00:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 62,498 | $22.12 | $1,382,343.26 |
DisclosureSEC source: 0001209191-22-048195 · doc4.xml · nonDerivative · entry 5 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,330 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $22.00 to $22.47.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2022 Filed Sep 1, 2022 00:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 34,758 | $1.24 | $43,099.92 |
DisclosureSEC source: 0001209191-22-048195 · doc4.xml · nonDerivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 15, 2022 Filed Sep 1, 2022 00:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 27,740 | $0.53 | $14,702.20 |
DisclosureSEC source: 0001209191-22-048195 · doc4.xml · nonDerivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,070 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 12, 2022 Filed Sep 1, 2022 00:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,003 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-22-048195 · doc4.xml · derivative · entry 9 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,740 Underlying: Common Stock · 14,003 shares Expires 2027-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · derivative.exercise_date: This option is exercisable as to vested and unvested shares. The option was granted on August 29, 2017 and 1/48th of the shares subject to the option vest monthly. Read SEC document |
| August 12, 2022 Filed Sep 1, 2022 00:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 14,003 | $22.00 | $308,066.00 |
DisclosureSEC source: 0001209191-22-048195 · doc4.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,330 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| August 12, 2022 Filed Sep 1, 2022 00:08 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 14,003 | $0.53 | $7,421.59 |
DisclosureSEC source: 0001209191-22-048195 · doc4.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| June 07, 2022 Filed Jun 8, 2022 21:00 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 21,000 | $0.00 Strike: $12.96 | $0.00 |
DisclosureSEC source: 0001209191-22-035080 · doc4.xml · derivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,000 Underlying: Common Stock · 21,000 shares Expires 2032-06-06 F1 · derivative.exercise_date: The option shall vest on June 7, 2023 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date. Read SEC document |
| January 21, 2022 Filed Mar 16, 2022 01:16 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | GrantStock Option (Right to Buy) · Derivative | 115,500 | $0.00 Strike: $14.22 | $0.00 |
DisclosureSEC source: 0001209191-22-019040 · doc4.xml · derivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,500 Underlying: Common Stock · 115,500 shares Expires 2032-01-20 F1 · derivative.exercise_date: 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of January 3, 2022 (the "Vesting Commencement Date"), subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:22 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 604 | $0.00 Strike: $0.53 | $0.00 |
DisclosureSEC source: 0001209191-21-066257 · doc4.xml · derivative · entry 5 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,743 Underlying: Common Stock · 604 shares Expires 2027-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · derivative.exercise_date: This option is exercisable as to vested and unvested shares. The option was granted on August 29, 2017 and 1/48th of the shares subject to the option vest monthly. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:22 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,396 | $0.00 Strike: $1.24 | $0.00 |
DisclosureSEC source: 0001209191-21-066257 · doc4.xml · derivative · entry 4 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,770 Underlying: Common Stock · 24,396 shares Expires 2030-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · derivative.exercise_date: 25% of the shares subject to the option vested on February 19, 2021, and 1/48th of the shares subject to the option will vest monthly thereafter. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:22 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | SaleCommon Stock | 25,000 | $27.89 | $697,217.50 |
DisclosureSEC source: 0001209191-21-066257 · doc4.xml · nonDerivative · entry 3 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,330 F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $27.75 to $28.2150.The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:22 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 604 | $0.53 | $320.12 |
DisclosureSEC source: 0001209191-21-066257 · doc4.xml · nonDerivative · entry 2 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,330 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| November 18, 2021 Filed Nov 23, 2021 01:22 UTC | Avidity Biosciences, Inc. RNA · Entity 11854 | Exercise / conversionCommon Stock | 24,396 | $1.24 | $30,251.04 |
DisclosureSEC source: 0001209191-21-066257 · doc4.xml · nonDerivative · entry 1 LEVIN ARTHUR A · CIK 0001181556 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,726 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercise and sale reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.